|1.||Protter, Andrew A: 10 articles (11/2008 - 06/2003)|
|2.||Dugar, Sundeep: 7 articles (03/2008 - 06/2004)|
|3.||Chakravarty, Sarvajit: 7 articles (03/2008 - 06/2004)|
|4.||Medicherla, Satyanarayana: 6 articles (11/2008 - 06/2004)|
|5.||Higgins, Linda S: 5 articles (11/2008 - 02/2002)|
|6.||Kapoun, Ann M: 5 articles (03/2008 - 10/2004)|
|7.||Ma, Jing Ying: 5 articles (01/2008 - 10/2004)|
|8.||Kerr, Irene: 4 articles (11/2008 - 07/2006)|
|9.||Li, Zhihe: 3 articles (12/2009 - 10/2004)|
|10.||Almirez, Ramona: 3 articles (01/2008 - 06/2004)|
11/01/2008 - "SD-282 treatment was additionally shown to significantly reduced expression of heat-shock protein-27 (HSP-27) and phospho-p38 in the tumor cells. "
11/01/2008 - "In a similar set of studies employing the SCIO-469 analogue SD-282 at 90 mg/kg/bid orally, histological assessment at the end of the study demonstrated a significant reduction in RPMI-8226 tumor growth and angiogenesis. "
01/01/2008 - "The aim of the present study was to evaluate the pharmacological activity of SD-282 on cytokine production in vitro as well as in 2 in vivo models of inflammation in order to illuminate the role of this particular inhibitor in diverse disease states. "
01/01/2008 - "SD-282 represents a valuable tool to elucidate the role of p38 MAP kinase in multiple models of inflammation."
03/01/2008 - "p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation."
02/05/2002 - "Suppression of inflammation with aspirin or inhibition of p38 MAPK with a selective inhibitor, SD-282, abolishes the increased neuronal vulnerability in APP751 transgenic mice. "
01/01/2008 - "We also show that administration of a p38α MAPK selective inhibitor, SD-282 at 30 or 90 mg/kg, twice a day for a period of four weeks beginning at the onset of asthma, significantly reduced the inflammation (p < 0.001); hyperplasia of airway epithelium (p < 0.05); goblet cell metaplasia and mucus hypersecretion (p < 0.001) and reduced lung remodeling and fibrosis (p < 0.01), alleviating the severity of lung damage as measured by a composite score (p < 0.05). "
06/01/2004 - "Repeated administration of 15 or 45 mg/kg SD-282 prevented the exacerbation of C-, but not Adelta-fiber, mediated thermal hyperalgesia. "
06/01/2004 - "Mechanical allodynia was reversed by acute and repeated administration of 15 and 45 mg/kg SD-282. "
10/01/2004 - "Similarly, 0.1-5mg/kg subcutaneous SD-282 in the hindpaw dose-dependently attenuated capsaicin-induced thermal hyperalgesia. "
10/01/2004 - "Intraperitoneal SD-282 (10-60 mg/kg) significantly and dose-dependently attenuated capsaicin-induced C-fiber mediated thermal hyperalgesia. "
06/01/2004 - "This study examined the effect of a p38alpha MAPK inhibitor, SD-282, on mechanical allodynia, thermal hyperalgesia, and formalin-evoked nociception in streptozotocin-induced diabetic rats. "
|5.||Brain Death (Brain Dead)
12/01/2009 - "Adult male Sprague Dawley rats were treated with vehicle (control, n=7) or SD-282 (40mg/kg, n=6), for 15min prior to the induction of brain death and maintained with ventilatory support for 3h. "
12/01/2009 - "The aim of this study was to determine the degree of p38 mitogen-activated protein kinase (p38 MAPK) activation in rat heart and lungs after experimentally induced brain death and to test whether SD-282, a synthetic and selective small molecule inhibitor of p38 MAPK, abrogates p38 MAPK activation invoked by this brain death model. "
12/01/2009 - "p38 MAPK inhibition with SD-282 decreases the pro-inflammatory response as represented by lower IL-6 and TNFalpha in plasma and lungs following brain death. "
|2.||p38 Mitogen-Activated Protein Kinases
|5.||Protein Kinases (Protein Kinase)
|6.||Collagen Type II (Type II Collagen)
|8.||Interleukin-6 (Interleukin 6)
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Heterologous Transplantation (Xenotransplantation)